|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Helicobacter pylori and colorectal neoplasia:Is there acausal link?显示文摘Ever since Helicobacter pylori(H. pylori) was recognized as an infectious cause of gastric cancer, there has been increasing interest in examining its potential role in colorectal carcinogenesis. Data from casecontrol and cross-sectional studies, mostly relying on hospital-based samples, and several meta-analyses have shown a positive statistical relationship between H. pylori infection and colorectal neoplasia. However, the possibility exists that the results have been influenced by bias, including the improper selection of patients and disparities with respect to potential confounders. While the evidence falls short of a definitive causal link, it appears that infection with H. pylori /H. pylori-related gastritis is associated with an increased, although modest, risk of colorectal adenoma and cancer. The pathogenic mechanisms responsible for this association remain uncertain. H. pylori has been detected in colorectal malignant tissues; however, the possibility that H. pylori is a direct activator of colonic carcinogenesis remains purely hypothetical. On the other hand, experimental data have indicated a series of potential oncogenic interactions between these bacteria and colorectal mucosa, including induction and perpetuation of inflammatory responses, alteration of gut microflora and release of toxins and/or hormonal mediators, such as gastrin, which may contribute to tumor formation. | Vasilios Papastergiou Stylianos Karatapanis Sotirios D Georgopoulos | 2016 | World Journal of Gastroenterology2016，22，2： | 22 |
| 2 | Treatment of Helicobacter pylori infection:Meeting the challenge of antimicrobial resistance显示文摘Treatment of Helicobacter pylori(H.pylori)infection is paramount for the management of prevalent gastrointestinal disorders including peptic ulcer disease and gastric cancer.Due to the wide increase in prevalence of H.pylori resistance to antibiotics,clarithromycin-based triple therapies are not any more suitable for unconditional empiric use,and should not be recommended,unless local resistance to this antibiotic is low(<20%).Alternative strategies have been proposed to overcome the issue of increasing clarithromycin resistance,and some of them are already implemented in clinical practice.These comprise:(1)adoption of novel,more effective,empirical treatments:bismuth quadruple,sequential,non-bismuth quadruple(concomitant),dual-concomitant(hybrid),and levofloxacin-based regimens,the latter mainly designated as second-line/rescue options;(2)perspectives for a susceptibility-guided(tailored)therapeutic approach based on culture-free molecular testing methods;and(3)adjunct use of probiotics to improve eradication rates.The present article is aimed to provide a comprehensive overview of current and emerging strategies in the treatment of H.pylori infection,focusing on the challenge of antimicrobial resistance. | Vasilios Papastergiou Sotirios D Georgopoulos Stylianos Karatapanis | 2014 | World Journal of Gastroenterology2014，20，29： | 18 |
| 3 | Treatment of Helicobacter pylori infection: Past, present and future显示文摘Helicobacter pylori(H. pylori) is a major human patho-gen associated with significant morbidity and mortal-ity. However, after decades of efforts, treatment of H. pylori remains a challenge for physicians, as there is no universally effective regimen. Due to the rising prevalence of antimicrobial resistance, mainly to clar-ithromycin, efficacy of standard triple therapies has declined to unacceptably low levels in most parts of the world. Novel regimens, specifically experimented to improve the therapeutic outcome against antibiotic-resistant H. pylori strains, are now recommended as first-line empirical treatment options providing high ef-ficacy(reportedly > 90% in intention to treat analysis) even in high clarithromycin resistance settings. These include the bismuth quadruple, concomitant, sequential and hybrid therapies. Due to the rapid development of quinolone resistance, levofloxacin-based regimens should be reserved as second-line/rescue options. Adjunct use of probiotics has been proposed in order to boost eradication rates and decrease occurrence of treatment-related side effects. Molecular testing meth-ods are currently available for the characterization of H. pylori therapeutic susceptibility, including genotypic detection of macrolide resistance and evaluation of the cytochrome P450 2C19 status known to affect the me-tabolism of proton pump inhibitors. In the future, use of these techniques may allow for culture-free, non-invasive tailoring of therapy for H. pylori infection. | Vasilios Papastergiou Sotirios D Georgopoulos Stylianos Karatapanis | 2014 | World Journal of Gastrointestinal Pathophysiology2014，5，4： | 11 |
| 4 | Nonbismuth Quadruple “Concomitant” Therapy Versus Standard Triple Therapy, Both of the Duration of 10 Days, for First-Line H. Pylori Eradication: A Randomized Trial显示文摘 | Sotirios Georgopoulos Vasilios Papastergiou Elias Xirouchakis Foteini Laoudi Philipos Lisgos Charikleia Spiliadi Nikitas Papantoniou Stylianos Karatapanis | 2013 | Journal of Clinical Gastroenterology2013，，3： | 3 |
| 5 | Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6显示文摘Hepatitis C virus(HCV) genotypes 4, 5 and 6 are mainly present in Africa, the Middle East and Asia and they have been less extensively studied with respect to epidemiology, natural disease history and therapeutic endpoints. Response rates to a 48-wk combined peginterferon/ribavirin treatment range to 40%-69% for HCV 4, 55%-60% for HCV 5 and 60%-90% for HCV 6. Response-guided schedules are recommended to optimize the outcomes of peginterferon/ribavirin treatment in HCV 4 and, in form of preliminarydata, for HCV 6, but no data are yet available to support such an individualization of therapy for HCV 5. Recently, the direct-acting antivirals(DAAs) with pan-genotypic activities simeprevir, sofosbuvir and daclatasvir have been recommended in triple regimens with peginterferon/ribavirin for the treatment of HCV genotypes 4 to 6 infections. In the future, DAA-based interferon-free therapies are awaited to drastically improve treatment outcomes in HCV. However, efforts to improve treatment outcomes with peginterferon/ribavirin should continue, as the HCV 4-6 infected population is mainly based in resource-limited settings with restricted access to the costly DAAs. | Vasilios Papastergiou Stylianos Karatapanis | 2015 | World Journal of Clinical Cases2015，3，3： | 3 |
| 6 | Current options for the treatment of Helicobacter pylori显示文摘 | Sotirios D Georgopoulos Vasilios Papastergiou Stylianos Karatapanis | 2013 | Expert Opinion on Pharmacotherapy2013，，2： | 3 |
| 7 | Nonbismuth Quadruple “Concomitant” Therapy Versus Standard Triple Therapy, Both of the Duration of 10 Days, for First-Line H. Pylori Eradication: A Randomized Trial显示文摘 | Sotirios Georgopoulos Vasilios Papastergiou Elias Xirouchakis Foteini Laoudi Philipos Lisgos Charikleia Spiliadi Nikitas Papantoniou Stylianos Karatapanis | 2013 | Journal of Clinical Gastroenterology2013，，3： | 2 |
| 8 | Periodontitis as a risk factor for cardiovascular Disease:The role of anti-phosphorylcholine and anti-cardiolipin antibodies显示文摘 | Kamoutsos K Papastergiou P Stefantidis S | | 0，，03： | 1 |
| 9 | On the design of a dual-band unequal power divider useful for mobile communications 显示文摘 | KAMPITAKI D G HATZIGAIDAS A T PAPASTERGIOU A I | 2007 | Electrical Engineering2007，89，6： | 1 |
| 10 | Deep- space transport protocol: a novel transport scheme for space DTNs显示文摘 | PAPASTERGIOU C PSARAS I TSAOUSSIDIS V | 2009 | Computer Communications2009，32，16： | 1 |
| 11 | An airborne radar power supply with contactless transfer of energy -- par- tII: converter design 显示文摘 | PAPASTERGIOU K D MACPHERSON D E | 2007 | IEEE Transcations on Industrial Electronics2007，54，5： | 1 |
| 12 | Mid-term clinical results of medial meniscus repair with the meniscus arrows in the unstable knee 显示文摘 | Koukoulias N Papastergiou S Kazakos K | 2007 | Knee Surg Sports Traumatol Arthrosc2007，15，2： | 1 |
| 13 | Current options for the treatment of Helicobacter pylori显示文摘 | Georgopoulos SD Papastergiou V Karatapanis S | 2013 | Exp Opin Pharmacother2013，14，2： | 1 |
| 14 | Risk stratification,management and outcomes of patients with non-ST elevation acute coronary syndrome: a Canadian teaching hospital perspective 显示文摘 | Shamiss Y Khaykin Y Papastergiou J | 2003 | Can J Cardiol2003，19，9： | 1 |
| 15 | Clinical results of meniscus repair with the meniscus arrow: a 4-to 8- year follow-up study 显示文摘 | Koukoulias N Papastergiou S Kazakos K | 2007 | Knee Surg Sports Traumatol Arthrosc2007，15，2： | 1 |
| 16 | Current options for the treatment of Helicobacter pylori显示文摘 | Georgopoulos SD Papastergiou V Karatapanis S | | 0，，02： | 1 |
| 17 | Current options for the treatment of Helicobacter pylori 显示文摘 | Georgopoulos SD Papastergiou V Karatapanis S | 2013 | Expert Opin Pharmacother2013，14，2： | 1 |
| 18 | Low conjunction of the cystic duct with the common bile duct: does it correlate with the formation of common bile duct stones?显示文摘 | I. Tsitouridis G. Lazaraki C. Papastergiou E. Pagalos G. Germanidis | 2007 | Surgical Endoscopy2007，，： | 1 |
| 19 | Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study显示文摘 | Vasilios Papastergiou Maria Stampori Phillipos Lisgos Crisostomos Pselas Kleopatra Prodromidou Stylianos Karatapanis | 2013 | European Journal of Gastroenterology & Hepatology2013，，7： | 1 |
| 20 | Low conjunction of the cystic duct with the common bile duct: does it correlate with the formation of common bile duct stones 显示文摘 | Tsitouridis I Lazaraki G Papastergiou C | 2007 | Surg Endosc2007，21，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员